Only a quarter of the estimated 4% of American adults who needed medication for opioid use disorder (MOUD) in 2022 received the treatment, according to a...
The US Food and Drug Administration (FDA) has approved Onyda XR (clonidine hydrochloride) for the treatment of attention-deficit/hyperactivity disorder (ADHD), drug manufacturer Tris Pharma announced in...